Current status of camptothecin derivatives as natural antitumor agents

Yaoxue Xuebao

Volumn 38, Issue 9, 2003, Pages 715-720

  Pan, Xian Dao ^a   Wang, Cun Ying ^b  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b CHINA UNIVERSITY OF MINING AND TECHNOLOGY   (China)

Author keywords

Antitumor activity; Camptothecin; Structure activity relationship (SAR)

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; TOPOTECAN;

ANIMAL; CELL CULTURE; CHEMISTRY; DRUG EFFECT; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 2342450702     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Wall ME, Wani MC, Cook CE, et al. Antitumor agent I. The isolation and structure of Camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminate [J]. J Amer Chem Soc , 1966, 88(16):3888-3890.
2. O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration [J]. Eur J Cancer, 1998, 34(10):1500- 1508.
3. Liu LF, Desai SD, Li TK, et al. Mechanism of action of camptothecin [J] . Ann N Y Acad Sci, 2000, 922:1-10.
4. Slichenmyer WJ, Rowinsky EK, Donehower RC. The current status of camptothecin analogues as antitumor agents [J]. J Nat Cancer Inst, 85(4):271-291.
5. Saijo N. Clinical trials of irinotecan hydrochloride in Japan [J]. Ann N Y Acad Sci, 1996, 803:292-305.
6. Broom C. Clinical studies of Topotecan [J]. Ann N Y Acad Sci, 1996, 803:264-271.
7. Mitsui I, Kumazawa E, Hirota Y, et al. A new water-soluble camptothecin derivative, DX-8 951 f, exhibits potent antitumor activity against human tumors in vitro and in vivo [J]. Jpn J Cancer Res, 1995, 86:(8)776-782.
8. Luzzio MJ, Besterman JM, Emerson DL, et al. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I [J]. J Med Chem, 1995, 38(3):395-401.
9. Lee JH, Lee JM, Lim KH, et al. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative [J]. Ann NY Acad Sci, 2000, 922:324-325.
10. Verschraegen CF, Gupta E, Loyer E et al. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin patents with refractory epithelial ovarian, tubal or peritoneal cancer [J]. Anticancer Drugs, 1999,10(4):375-383.
11. Takimoto CH, Thomas R. The clinical development of 9-aminocamptothecin [J] . Ann N Y Acad Sci, 2000, 922:224 -236.
12. Penco S, Zunino F, Merlini L, et al. Camptothecin derivatives having antitumor activity [P] . US pat: 6242457, 2001-06-05.
13. Dallavalle S, Ferrari A, Biasotti B, et al. Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumoractivity [J] . J Med Chem, 2001, 44(20):3264-3274.
14. Lavergne O, Laurence LG, Rodas FP, et al. Homecamptothecins: synthesis and antitumor activity of novel E-ring-modified camplothecin analogues [J]. J Med Chem, 1998, 41(27):5410-5419.
15. Sawada S, Yokokura T. Synthesis of CPT-11 (Irinotecan hydrochloride trihydrate) [J]. Ann N Y Acad Sci, 1996, 803:13-28.
16. Wall ME, Wall MC. Camptothecin: discovery to clinic [J]. Ann N Y Acad Sci, 1996, 803: 1-12.
17. Wall ME, Wani MC. Camptothecin and taxol : discovery to clinic-thirteenth Bruce F. Cain memorial award lecture [J] . Cancer Res, 1995, 55(1-3):753-760.
18. Kohn KW, Pommier Y. Molecular and biological determinants of the cytotoxic actions of camptothecins [J]. Ann NY Acad Sci, 2000, 922:11-26.
19. Burke TG, Bom AD. Camptothecin design and delivery approaches for elevating anti-topoisomerase I activities in vivo [J]. Ann NY Acad Sci, 2000, 922:36-45.
20. Cao ZS, Pantazis P, Mendoza J, et al. Structure-activity relationship of alkyl Camptothecin esters [J]. Ann NY Acad Sci, 2000, 922:122-135.
21. Wall ME, Wani MC. Water-soluble esters of camptothecin compound [P]. US Pat: 6040313, 2000-03-21.
22. Yang LX, Pan XD, Wang HJ. Camptothecin derivatives [P]. US pat: 6350756, 2002-02-26.
23. Yang LX, Pan XD, Wang HJ. Nitrogen-based Camptothecin derivatives [P]. US pat; 6403604, 2002-06-11.
24. Yang LX, Pan XD, Wang HJ. Novel camptothecin derivatives, part 1: oxyalkanoic acid esters of camptothecin and their in vitro and in vivo antitumor activity [J]. Bioorg Med Chem Lett, 2002, 12(9):1241-1244.
25. Bailly C, Laine W, Baldeyrou B, et al. A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38 [J]. Anti Cancer Drug Des, 2001,16(1): 27-36.
26. Lavergne O, Demarquay D, Bailly C, et al. The novel silatecan 7-tert-butyl dimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity [J]. J Med Chem, 2000, 43 (11):2285-2289.
27. Lerchen HG, Baumgarten J, Bruch K, et al. Design and optimization of 20-0-linked camptothecin glycoconjugates as anticancer agents [J] . J Med Chem, 2001, 44(24):4186-4195.
28. Bailly C. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs [J]. Crit Rev Oncol Hematol, 2003, 45(1):91-108.